Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study.
2021
272Background: Atezolizumab-bevacizumab is the new standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, the optimal sequence of therapy after disease progr...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
16
References
6
Citations
NaN
KQI